title: Lansoprazole in globus pharyngeus: double-blind, randomized, placebo-controlled trial.
abstract: OBJECTIVE
  To evaluate the effectiveness of once-daily lansoprazole in the typical globus pharyngeus patient, who presents with a normal head and neck examination and without other sinister otolaryngologic complaints.
  
  
  METHODS
  Prospective, randomized, double-blind, placebo-controlled trial.
  
  
  METHODS
  Outpatient otolaryngology office practice.
  
  
  METHODS
  After meeting the inclusion criteria, patients were randomized to a 3-month course of either treatment (30 mg lansoprazole daily) or placebo (lactose). All patients were given a medication diary and instructed to take the medication daily on waking. During the office visit, counseling regarding lifestyle modifications for gastroesophageal reflux disease was provided to all patients.
  
  
  METHODS
  The Glasgow-Edinburgh Throat Scale questionnaire was given prior to treatment and at 1- and 3-month intervals during treatment.
  
  
  RESULTS
  Forty patients were enrolled between June 2005 and December 2006. Nineteen patients were randomized to the lansoprazole treatment arm, whereas 21 were enrolled in the placebo arm. Both groups were similar with regard to age, sex, and smoking history. The globus symptom score improved an average of 6.7 of 70 points in the treatment group and 2.9 points in the placebo group. There was no clinically or statistically significant difference between the two groups at any time point.
  
  
  CONCLUSIONS
  The globus pharyngeus patient who presents with a normal head and neck examination and without sinister otolaryngologic complaints does not benefit from once-daily lansoprazole therapy.
authors.affiliation: Department of Otolaryngology, University of Alberta, Edmonton, Alberta.
authors.forename: Jaymi
authors.initials: J
authors.lastname: Dumper
authors.forename: Brad
authors.initials: B
authors.lastname: Mechor
authors.forename: Jason
authors.initials: J
authors.lastname: Chau
authors.forename: Michael
authors.initials: M
authors.lastname: Allegretto
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage*; D000328:Adult; D000553:Ambulatory Care; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D010608:Pharyngeal Diseases / Q000175:diagnosis* / Q000188:drug therapy*; D010614:Pharynx / Q000187:drug effects / Q000503:physiopathology; D011336:Probability; D011446:Prospective Studies; D011788:Quality of Life; D012016:Reference Values; D012307:Risk Factors; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D064747:Lansoprazole